Gufic BioScience

Gufic Biosciences reported a Q4 FY25 revenue of ₹205 crores, a 5.1% increase year-on-year. However, profitability saw a significant decline, with EBITDA falling 23.1% to ₹27 crores and PAT dropping 60% to ₹8 crores. The EBITDA margin contracted to 13.17% from 18% in Q4 FY24. For the full fiscal year FY25, revenue grew marginally by 1.6% to ₹819.8 crores, while PAT decreased by 18.9% to ₹69.9 crores, with the PAT margin at 8.53%.

The newly capitalized Indore plant significantly impacted Q4 FY25 profitability, absorbing ₹8 crores in incremental fixed costs (interest, depreciation, salaries). Management expects these costs to total ₹36 crores for FY26. The plant aims for EBITDA breakeven in FY26 at approximately 30% capacity utilization, with net profit breakeven targeted for FY27. For FY26, Indore is projected to contribute a minimum of ₹100-150 crores in revenue, primarily from domestic markets. The facility's peak revenue potential is estimated at ₹800-900 crores, reaching 70-75% capacity utilization by FY28-29, contingent on international regulatory approvals.

Gufic's Botulinum Toxin Type A, Stunnox, has treated 50,000 patients since its launch. The company aims to achieve a 20-22% market share in aesthetics and 25-26% market penetration in neurology this year. The Botulinum Toxin business currently contributes 3-4% of Gufic's total revenue, with gross margins of 80-85%. Management targets ₹100 crore in revenue from this segment within the next three years, driven by increased awareness and expanded therapeutic indications.

The fertility cluster is a key growth area, contributing approximately 25% to domestic revenue. Gufic is initiating clinical trials for Urofollitropin Alpha (recombinant FSH) with approvals expected next year. Trials for Supergraf (India's purest HMG) are underway, with results anticipated by the end of this year. The company also expects Guficin Alpha, an immunomodulator for recurrent implantation failure, to contribute ₹8-9 crores in revenue this year, as it works to establish its market presence.

Gufic is aggressively expanding its international footprint, aiming to increase its revenue share from the current 16-18% to 25% in the next 2-3 years. Key initiatives include appointing a President of International Business, signing a distribution agreement covering 17 LATAM countries, and securing seven product approvals in Myanmar, Sri Lanka, and Cambodia. The company is also setting up rep offices in Vietnam and evaluating a presence in the Philippines, with a focus on regulated markets for Indore's output, expecting commercial revenue from these markets by late FY26 or early FY27.

The critical care cluster, which accounts for over 50% of domestic revenue, is optimizing its sales teams to focus on high-potential hospitals. Cavim leads the Ceftazidime+Avibactam segment in 195 centers, and Gufic holds top positions in antifungals like Caspofungin and Micafungin. The Sparsh cluster is launching contrast-media offerings, with a soft launch already providing positive feedback. This product line is expected to become a 5-6% contributor to the critical care segment in the next 2-3 years, with iodine-based products alone projected to generate ₹15-20 crores in revenue.

While gross margins have increased, overall profitability was pressured by higher fixed costs from the Indore plant and significant price erosion in 10-12 key molecules, including Meropenem, Human Chorionic Gonadotropin, Enoxaparin, and Cavim. The selling rate for Cavim, for instance, dropped from ₹1,200 to ₹680-700. Management believes this price erosion has bottomed out since September-December 2024, and expects revenue growth in FY26 to be driven by increased volumes and contributions from the Indore plant.